Fisher & Paykel Healthcare manufactures, designs, and markets medical devices for respiratory care, acute care, and treatment of obstructive sleep apnea. The company operates through two segments: Hospital and Homecare. It provides infant respiratory products, such as resuscitation, continuous positive airway pressure (CPAP) therapy, and nasal high flow therapy products. In addition, the company offers hospital products, including humidification products, breathing circuits, chambers, masks, nasal cannulas, surgical, accessories, and interfaces; and homecare products that include masks, CPAP devices, data management products, humidifiers, and accessories. The company is mainly active in North America (45% of revenues), Europe and Asia-Pacific. The company has ca. 7,000 employees and is headquartered in Auckland, New Zealand.
Fisher & Paykel provides lifesaving treatments and contributes to better quality of life (in the case of treating sleep apnea). The company delivers a key treatment (nasal high flow therapy) for adults and babies at a time when they are most vulnerable. Neonatal respiratory distress syndrome is the leading cause of death in premature infants. The company also provides oxygen therapy for adults and devices to control sleep apnea. In July 2019, The Lancet Respiratory Medicine journal estimated that 936 million adults aged 30–69 years (men and women) have mild to severe obstructive sleep apnea (OSA). This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million. In addition, 3% of all children suffer from OSA. Complications that make sleep apnea a serious medical condition include daytime fatigue, high blood pressure or heart problems. It is a growing medical issue with a clear negative impact on quality of life.